|
1
|
Wang HH, Garruti G, Liu M, Portincasa P
and Wang DQ: Cholesterol and lipoprotein metabolism and
atherosclerosis: Recent advances in reverse cholesterol transport.
Ann Hepatol. 16 (Suppl 1):S27–S42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Galkina E and Ley K: Immune and
inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol.
27:165–197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Toth PP: Subclinical atherosclerosis: What
it is, what it means and what we can do about it. Int J Clin Pract.
62:1246–1254. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ambrose JA and Barua RS: The
pathophysiology of cigarette smoking and cardiovascular disease: An
update. J Am Coll Cardiol. 43:1731–1737. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Balistreri CR, Caruso C and Candore G: The
role of adipose tissue and adipokines in obesity-related
inflammatory diseases. Mediators Inflamm. 2010:8020782010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gustafson B: Adipose tissue, inflammation
and atherosclerosis. J Atheroscler Thromb. 17:332–341. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wannamethee SG, Lowe GDO, Shaper AG,
Rumley A, Lennon L and Whincup PH: Associations between cigarette
smoking, pipe/cigar smoking, and smoking cessation, and haemostatic
and inflammatory markers for cardiovascular disease. Eur Heart J.
26:1765–1773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mazurek T, Zhang L, Zalewski A, Mannion
JD, Diehl JT, Arafat H, Sarov-Blat L, O'Brien S, Keiper EA, Johnson
AG, et al: Human epicardial adipose tissue is a source of
inflammatory mediators. Circulation. 108:2460–2466. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Andersen T, Ueland T, Ghukasyan Lakic T,
Åkerblom A, Bertilsson M, Aukrust P, Michelsen AE, James SK, Becker
RC, Storey RF, et al: C-X-C ligand 16 is an independent predictor
of cardiovascular death and morbidity in acute coronary syndromes.
Arterioscler Thromb Vasc Biol. 39:2402–2410. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bakogiannis C, Sachse M, Stamatelopoulos K
and Stellos K: Platelet-derived chemokines in inflammation and
atherosclerosis. Cytokine. 122:1541572019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma A, Pan X, Xing Y, Wu M, Wang Y and Ma
C: Elevation of serum CXCL16 level correlates well with
atherosclerotic ischemic stroke. Arch Med Sci. 10:47–52. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cybulsky MI, Iiyama K, Li H, Zhu S, Chen
M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW and Milstone
DS: A major role for VCAM-1, but not ICAM-1, in early
atherosclerosis. J Clin Invest. 107:1255–1262. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ludwig A, Schulte A, Schnack C, Hundhausen
C, Reiss K, Brodway N, Held-Feindt J and Mentlein R: Enhanced
expression and shedding of the transmembrane chemokine CXCL16 by
reactive astrocytes and glioma cells. J Neurochem. 93:1293–1303.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hofnagel O, Engel T, Severs NJ, Robenek H
and Buers I: SR-PSOX at sites predisposed to atherosclerotic lesion
formation mediates monocyte-endothelial cell adhesion.
Atherosclerosis. 217:371–378. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lehrke M, Millington SC, Lefterova M,
Cumaranatunge RG, Szapary P, Wilensky R, Rader DJ, Lazar MA and
Reilly MP: CXCL16 is a marker of inflammation, atherosclerosis, and
acute coronary syndromes in humans. J Am Coll Cardiol. 49:442–449.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Holmøy T, Løken-Amsrud KI, Bakke SJ,
Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T,
Šaltytė Benth J, et al: Inflammation markers in multiple sclerosis:
CXCL16 reflects and may also predict disease activity. PLoS One.
8:e750212013. View Article : Google Scholar
|
|
17
|
Canton J, Neculai D and Grinstein S:
Scavenger receptors in homeostasis and immunity. Nat Rev Immunol.
13:6212013. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sheikine Y and Sirsjö A: CXCL16/SR-PSOX-a
friend or a foe in atherosclerosis? Atherosclerosis. 197:487–495.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sheikine Y, Bang CS, Nilsson L, Samnegård
A, Hamsten A, Jonasson L, Eriksson P and Sirsjö A: Decreased plasma
CXCL16/SR-PSOX concentration is associated with coronary artery
disease. Atherosclerosis. 188:462–466. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
National Research Council (US) Committee
for the Update of the Guide for the Care and Use of Laboratory
Animals, . Guide for the Care and Use of Laboratory Animals. 8th
edition. National Academies Press (US); Washington, DC: 2011
|
|
21
|
Crossley BM, Bai J, Glaser A, Maes R,
Porter E, Killian ML, Clement T and Toohey-Kurth K: Guidelines for
Sanger sequencing and molecular assay monitoring. J Vet Diagn
Invest. 32:767–775. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thouas GA, Trounson AO and Jones GM:
Effect of female age on mouse oocyte developmental competence
following mitochondrial injury. Biol Repord. 73:366–373. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stewart-Phillips JL, Lough J and Skamene
E: Genetically determined susceptibility and resistance to
diet-induced atherosclerosis in inbred strains of mice. J Lab Clin
Med. 112:36–42. 1988.PubMed/NCBI
|
|
24
|
Zhou YG, Lan XH, Li X and Xu R:
Establishment and evaluation of an atherosclerosis model in rats.
Pharm J Chin PLA. 27:399–403. 2011.
|
|
25
|
Wang W, Zhang ZZ, Wu Y, Wang RQ, Chen JW,
Chen J, Zhang Y, Chen YJ, Geng M, Xu ZD, et al:
(−)-Epigallocatechin-3-gallate ameliorates atherosclerosis and
modulates hepatic lipid metabolic gene expression in apolipoprotein
E knockout mice: Involvement of TTC39B. Front Pharmacol. 9:1952018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ishak K, Baptista A, Bianchi L, Callea F,
De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, et al:
Histological grading and staging of chronic hepatitis. J Hepatol.
22:696–699. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Munjal A and Khandia R: Atherosclerosis:
Orchestrating cells and bimolecules involved in its activation and
inhibition. Adv Protein Chem Struct Biol. 120:85–122. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Emini Veseli B, Perrotta P, De Meyer GRA,
Roth L, Van der Donckt C, Martinet W and De Meyer GRY: Animal
models of atherosclerosis. Eur J Pharmacol. 816:3–13. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Getz GS and Reardon CA: Apoprotein E as a
lipid transport and signaling protein in the blood, liver, and
artery wall. J Lipid Res. 50 (Suppl):S156–S161. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang HL, Wu LM and Wu J: Cross-talk
between apolipoprotein E and cytokines. Mediators Inflamm.
2011:9490722011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang XY, Yang YZ, Tan JM, Yuan ZH and Wang
ZY: The estbablishment of an Atheroscleroti murine model and
pathologieal observation of plaques by laser seaning confoeal
mieroseopy. Chin J Arterioseler. 4:54–57. 1996.
|
|
32
|
Roebuck KA: Oxidant stress regulation of
IL-8 and ICAM-1 gene expression: Differential activation and
binding of the transcription factors AP-1 and NF-kappaB (Review).
Int J Mol Med. 4:223–230. 1999.PubMed/NCBI
|
|
33
|
Gu L, Okada Y, Clinton SK, Gerard C,
Sukhova GK, Libby P and Rollins BJ: Absence of monocyte
chemoattractant protein-1 reduces atherosclerosis in low density
lipoprotein receptor-deficient mice. Mol Cell. 2:275–281. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yadav A, Saini V and Arora S: MCP-1:
Chemoattractant with a role beyond immunity: A review. Clin Chim
Acta. 411:1570–1579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kanda H, Tateya S, Tamori Y, Kotani K,
Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K and
Kasuga M: MCP-1 contributes to macrophage infiltration into adipose
tissue, insulin resistance, and hepatic steatosis in obesity. J
Clin Invest. 116:1494–1505. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cushing SD, Berliner JA, Valente AJ,
Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ and Fogelman
AM: Minimally modified low density lipoprotein induces monocyte
chemotactic protein 1 in human endothelial cells and smooth muscle
cells. Proc Natl Acad Sci USA. 87:5134–5138. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shyy YJ, Hsieh HJ, Usami S and Chien S:
Fluid shear stress induces a biphasic response of human monocyte
chemotactic protein 1 gene expression in vascular endothelium. Proc
Natl Acad Sci USA. 91:4678–4682. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Piga R, Naito Y, Kokura S, Handa O and
Yoshikawa T: Short-term high glucose exposure induces
monocyte-endothelial cells adhesion and transmigration by
increasing VCAM-1 and MCP-1 expression in human aortic endothelial
cells. Atherosclerosis. 193:328–334. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhu Y, Xian X, Wang Z, Bi Y, Chen Q, Han
X, Tang D and Chen R: Research progress on the relationship between
atherosclerosis and inflammation. Biomolecules. 8:802018.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Preiss DJ and Sattar N: Vascular cell
adhesion molecule-1: A viable therapeutic target for
atherosclerosis? Int J Clin Pract. 61:697–701. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Marzolla V, Armani A, Mammi C, Moss ME,
Pagliarini V, Pontecorvo L, Antelmi A, Rosano G, Jaffe IZ and
Caprio M: Essential role of ICAM-1 in aldosterone-induced
atherosclerosis. Int J Cardiol. 232:233–242. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nakashima Y, Raines EW, Plump AS, Breslow
JL and Ross R: Upregulation of VCAM-1 and ICAM-1 at
atherosclerosis-prone sites on the endothelium in the
ApoE-deficient mouse. Arterioscler Thromb Vasc Biol. 18:842–851.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Iiyama K, Hajra L, Iiyama M, Li H,
DiChiara M, Medoff BD and Cybulsky MI: Patterns of vascular cell
adhesion molecule-1 and intercellular adhesion molecule-1
expression in rabbit and mouse atherosclerotic lesions and at sites
predisposed to lesion formation. Circ Res. 85:199–207. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fotis L, Agrogiannis G, Vlachos IS,
Pantopoulou A, Margoni A, Kostaki M, Verikokos C, Tzivras D,
Mikhailidis DP and Perrea D: Intercellular adhesion molecule
(ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 at the early
stages of atherosclerosis in a rat model. In Vivo. 26:243–250.
2012.PubMed/NCBI
|
|
45
|
Yi GW, Zeng QT, Mao XB, Cheng M, Yang XF,
Liu HT, Mao Y, Guo M, Ji QW and Zhong YC: Overexpression of CXCL16
promotes a vulnerable plaque phenotype in apolipoprotein E-knockout
mice. Cytokine. 53:320–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wuttge DM, Zhou X, Sheikine Y, Wågsäter D,
Stemme V, Hedin U, Stemme S, Hansson GK and Sirsjö A:
CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and
scavenger receptor expressed in atherosclerotic lesions.
Arterioscler Thromb Vasc Biol. 24:750–755. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Vandooren J, Van den Steen PE and
Opdenakker G: Biochemistry and molecular biology of gelatinase B or
matrix metalloproteinase-9 (MMP-9): The next decade. Crit Rev
Biochem Mol Biol. 48:222–272. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Patterson J and Hubbell JA: Enhanced
proteolytic degradation of molecularly engineered PEG hydrogels in
response to MMP-1 and MMP-2. Biomaterials. 31:7836–7845. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lindsey ML and Zamilpa R: Temporal and
spatial expression of matrix metalloproteinases and tissue
inhibitors of metalloproteinases following myocardial infarction.
Cardiovasc Ther. 30:31–41. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Van Lint P and Libert C: Chemokine and
cytokine processing by matrix metalloproteinases and its effect on
leukocyte migration and inflammation. J Leukoc Biol. 82:1375–1381.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gong Y, Hart E, Shchurin A and Hoover-Plow
J: Inflammatory macrophage migration requires MMP-9 activation by
plasminogen in mice. J Clin Invest. 118:3012–3024. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li F, Sun XJ, Xie H, Wang Y and Zhang YK:
The relationship between chronic periodontitis and the instability
of carotid atherosclerotic plaque by serum level of MMP-9, MCP-1
and MMP-7. Shanghai Kou Qiang Yi Xue. 24:589–593. 2015.(In
Chinese). PubMed/NCBI
|
|
53
|
Loftus IM, Naylor AR, Goodall S, Crowther
M, Jones L, Bell PR and Thompson MM: Increased matrix
metalloproteinase-9 activity in unstable carotid plaques. A
potential role in acute plaque disruption. Stroke. 31:40–47. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Rao VH, Kansal V, Stoupa S and Agrawal DK:
MMP-1 and MMP-9 regulate epidermal growth factor-dependent collagen
loss in human carotid plaque smooth muscle cells. Physiol Rep.
2:e002242014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Huang Z, Wang L, Meng S, Wang Y, Chen T
and Wang C: Berberine reduces both MMP-9 and EMMPRIN expression
through prevention of p38 pathway activation in PMA-induced
macrophages. Int J Cardiol. 146:153–158. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Gostiljac D, Dorđević PB, Djurić D,
Peruničić J, Lasica R, Colak E, Canovic F, Srećković VD, Ilić M and
Obrenović R: The importance of defining serum MMP-9 concentration
in diabetics as an early marker of the rupture of atheromatous
plaque in acute coronary syndrome. Acta Physiol Hung. 98:91–97.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
NCD Risk Factor Collaboration (NCD-RisC),
. Trends in adult body-mass index in 200 countries from 1975 to
2014: A pooled analysis of 1698 population-based measurement
studies with 19·2 million participants. Lancet. 387:1377–1396.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Öörni K, Lehti S, Sjövall P and Kovanen
PT: Triglyceride-rich lipoproteins as a source of proinflammatory
lipids in the arterial wall. Curr Med Chem. 26:1701–1710. 2019.
View Article : Google Scholar
|
